Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Micah Joel Maxwell, M.D., Ph.D.

Headshot of Micah Joel Maxwell
  • Instructor of Oncology


Oncology, Pediatric Oncology, Sarcoma

Research Interests

High-risk Rhabdomyosarcoma; and Neuroblastoma Metabolomics more


The Johns Hopkins Hospital

600 N. Wolfe Street
Baltimore, MD 21287 map


Micah Maxwell, MD, PhD, is an Instructor in the Division of Pediatric Oncology. He completed the MD/PhD program at Johns Hopkins in 2012, followed by a three-year pediatric residency at the Children’s Hospital of Pittsburgh. In 2015, he returned to Johns Hopkins as a Pediatric Hematology-Oncology Fellow. He was Chief Fellow 2017-2018, and Pediatric Sarcoma Fellow from 2018-2019. 

Dr. Maxwell’s research focuses on the metabolomics of pediatric solid tumors, particularly high-risk rhabdomyosarcoma and neuroblastoma, both of which continue to have poor outcomes despite highly aggressive treatment regimens. Metabolomics – the study of the tiniest biochemicals present in cells, tissues and body fluids, and the role they play in driving cancer development – offers a new approach to understanding and managing disease and holds great promise for future targeted therapies to treat cancers. Currently, Dr. Maxwell is applying this approach to neuroblastoma and rhabdomyosarcoma, and he is excited about the potential to harness the same techniques to identify new therapeutic options in other pediatric solid tumors as well. Additionally, he is working on an evidence-based protocol for addressing the nutritional needs of patients with high-risk neuroblastoma. more


  • Instructor of Oncology

Departments / Divisions



  • MD PhD; Johns Hopkins University School of Medicine (2012)


  • Pediatrics; Children's Hospital of Pittsburgh of UPMC (2015)


  • Pediatric Oncology; Johns Hopkins University School of Medicine (2019)
  • Pediatric Oncology; National Institutes of Health (2019)

Research & Publications

Selected Publications

Kim S, Kim SF, Maag D, Maxwell MJ, Resnick AC, Juluri KR, Cha SH, Chakraborty A, Koldobskiy MA, Barrow R., Snowman AM, Snyder SH. Amino acid signaling to mTor is mediated by inositol polyphosphate multikinase. Cell Metabolism 2011. 13(2): 215-21.

Maag D*,  Maxwell MJ*, Hardesty DA, Boucher K L, Choudhari N, Hanno AG, Ma J F, Snowman AS, Pietropaoli JW, Xu R, Storm PB, Saiardi A, Snyder SH, Resnick AC. Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB. Proc. Natl. Acad. Sci USA 2011. 108(4): 1391-6. [*Contributed equally to this work].

Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, Juluri KR, Maag D, Kim S, Huang AS, Dailey MJ., Saleh M, Snowman AM, Moran TH, Mezey E, Snyder SH. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell 2010. 143(6): 897-910.

Holmes KW, Hales R, Chu S, Maxwell MJ, Mogayzel PJ Jr, Zeitlin PL. Modulation of Sp1 and Sp3 in lung epithelial cells regulates ClC-2 chloride channel expression. Am. J. Respir. Mol. Cell Bio 2003. 29(4): 499-505.

Activities & Honors


  • Ann E. Thompson Pediatric Critical Care Medicine Award, Children’s Hospital of Pittsburgh of UPMC, 2015
  • Chief Fellow, 2017
  • Johns Hopkins University Pediatric Oncology Sarcoma Fellowship, 2018
  • St. Baldrick’s Foundation Fellowship Award, 2019
  • Optimist International Research Fellowship, 2019


  • Member, American Association for Cancer Research, 2017 - 2019
  • Member, Children’s Oncology Group, 2018 - 2019

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button